Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluconazole vs Amphotericin B for Acute Cryptococcal Meningitis
NCT00002068Phase 3Completed
- Sponsor
- Pfizer
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of fluconazole in cryptococcal meningitis (2 arms), sponsored by Pfizer. Primary endpoint: Mycological Cure (CSF Culture Conversion) at 10 weeks. Status: completed.
02
Drugs
fluconazole
03
Conditions
cryptococcal meningitis
Beyond the preview
Go deeper on NCT00002068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002068.